ELUCIDA ONCOLOGY
Elucida Oncologyโข is focused on transforming outcomes for patients with primary solid tumor and metastatic cancer. They are leveraging the novel Target or Clearโข capabilities of our ultra-small C-Dot cancer-targeting particle platform across diagnostic imaging, surgical and a wide range of therapeutic applications.
ELUCIDA ONCOLOGY
Social Links:
Industry:
Biotechnology
Founded:
2014-01-01
Address:
Monmouth Junction, New Jersey, United States
Country:
United States
Website Url:
http://www.elucidaoncology.com
Total Employee:
11+
Status:
Active
Total Funding:
72 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Similar Organizations
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-22 | Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer |
Official Site Inspections
http://www.elucidaoncology.com Semrush global rank: 719.28 K Semrush visits lastest month: 57.3 K
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Elucida Oncology"
Elucida Oncology - Crunchbase Company Profile
Elucida Oncology focuses on transforming outcomes for patients with primary solid tumors and metastatic cancer. The company utilizes the novel target or clear capabilities of its ultra-small C-Dot cancer-targeting particle platform across โฆSee details»
Elucida Oncology Company Profile | Management and Employees โฆ
Www.elucidaoncology.com Elucida Oncology Profile and History Elucida Oncology, Inc., is a privately held, clinical-stage biotechnology company focused on developing and โฆSee details»
Elucida Oncology - Overview, News & Similar companies - ZoomInfo
Apr 20, 2023 Elucida Oncology contact info: Phone number: (732) 823-1182 Website: www.elucidaoncology.com What does Elucida Oncology do? Elucida Oncology, Inc., is a โฆSee details»
Elucida Oncology, Inc. | LinkedIn
Elucida Oncology, Inc. | 2,101 followers on LinkedIn. A Clinical-Stage Biotechnology Company Targeting Cancer with Precision Engineered C'Dot Drug Conjugates | Elucida Oncology, Inc., โฆSee details»
Elucida Oncology, Inc. Information - RocketReach
Elucidaoncology.com; View Similar People. Related Companies Princeton BioMeditech Corporation. 26 $12.2m Synbio Technologies. 31 $18.3m Provid Pharmaceuticals. 13 $10m โฆSee details»
Elucida Oncology - PitchBook
Elucida Oncology General Information Description. Developer of cancer therapeutics designed to target cancer with precision engineering technology. The company's platform produces novel โฆSee details»
Elucida Oncology Company Profile - Office Locations ... - Craft
Elucida Oncology has 5 employees at their 1 location and $72 m in total funding,. See insights on Elucida Oncology including office locations, competitors, revenue, financials, executives, โฆSee details»
Elucida Oncology Company Profile -Sales, Contacts, Competitors
Elucida Oncology is in the Biotechnical Research, Commercial industry within the Engineering, Accounting, Research, and Management Services sector and has been in business for โฆSee details»
Elucida Oncology CEO and Key Executive Team | Craft.co
Elucida Oncology's President and Chief Executive Officer, Director is Geno Germano. Other executives include Gregory P. Adams, Chief Scientific Officer; Robert A. Essner, Chairman โฆSee details»
Elucida Oncology Inc Overview - Salary.com
Discover essential details about Elucida Oncology Inc, including address, contact, and journey of our company's evolution.See details»
Elucida Oncology: leading the way in cancer theranostics - Nature
Elucida Oncology, Inc. Geno Germano, President and CEO, Elucida Oncology, Inc., New York, NY, USA, Tel: +1-646-606-2421, Website: www.elucidaoncology.comSee details»
Elucida Oncology Announces Three Key Additions to Its Board of ...
Apr 29, 2021 MONMOUTH JUNCTION, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, โฆSee details»
Elucida Oncology Provides Corporate Update and Outlines Key โฆ
Jan 5, 2022 Enrolling third dose level in Phase 1/2 dose escalation study of ELU001, our lead clinical program targeting solid tumors overexpressing folate receptor alpha (FRฮฑ) Interim โฆSee details»
Elucida Oncology Announces Three Key Additions to Its Board
Apr 29, 2021 MONMOUTH JUNCTION, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, โฆSee details»
Elucida Oncology Closes $44 Million Series A-1 Financing - Yahoo โฆ
Jan 12, 2021 MONMOUTH JUNCTION, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, โฆSee details»
Elucida Oncology to Present at the 42nd Annual J.P. Morgan
Dec 27, 2023 MONMOUTH JUNCTION, N.J., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in...See details»
Elucida Oncology to Present at the Evercore ISI 2024 ... - BioSpace
Feb 15, 2024 MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted โฆSee details»
Elucida Oncology Closes $44 Million Series A-1 Financing
Jan 12, 2021 Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today it has closed a $44 million Series A-1 financing. โฆSee details»
Elucida Oncology Closes $44 Million Series A-1 Financing
Jan 12, 2021 MONMOUTH JUNCTION, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, โฆSee details»
Elucida Oncology to Present New Clinical and Preclinical Data at โฆ
Apr 11, 2023 Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that two abstracts featuring ELU001, its โฆSee details»